Compare SCZM & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCZM | COLL |
|---|---|---|
| Founded | N/A | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | SCZM | COLL |
|---|---|---|
| Price | $7.64 | $32.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 540.9K | ★ 547.7K |
| Earning Date | 05-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $22.30 | $5.93 |
| Revenue Next Year | $69.17 | N/A |
| P/E Ratio | ★ $14.27 | $19.32 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $6.90 | $23.23 |
| 52 Week High | $17.65 | $50.79 |
| Indicator | SCZM | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 34.66 | 24.32 |
| Support Level | $6.90 | $31.01 |
| Resistance Level | $12.74 | $32.92 |
| Average True Range (ATR) | 0.67 | 1.30 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 17.80 | 1.07 |
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.